The Best in Science News and Amazing Breakthroughs
The US Food and Drug Administration has given the green light for a popular anti-obesity drug to be used to prevent serious heart conditions for the first time, in a move likely to expand insurance coverage.
Approval was based on a multinational trial involving 17,500 patients, with about half assigned the drug and the other half given a. Both groups received standard medical care for the management of blood pressure and cholesterol, and both received healthy lifestyle counselling on diet and exercise. Insurers"should have been providing coverage for anti-obesity medications prior to the announcement. Now, there should be no doubt that this treatment must be covered. Lives are at stake," the group said.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
FDA approves Wegovy to reduce heart attack and stroke riskBerkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Les mer »
FDA approves Wegovy for cardiovascular diseaseThe FDA on Friday approved Wegovy to lower the risk of cardiovascular death for people who are obese or overweight, a first of its kind classification.
Les mer »
FDA approves Wegovy for lowering heart attack and stroke risk in overweight patientsThe popular weight-loss drug can now be used to reduce the risk of stroke, heart attacks and other serious cardiovascular problems in patients who are overweight or who have obesity, the FDA said.
Les mer »
FDA approves Wegovy to reduce heart attack and stroke riskThe U.S. Food and Drug Administration approved a label change that expands the use of the drug in Wegovy. It was previously approved to treat obesity.
Les mer »
FDA approves weight-loss drug Wegovy to reduce heart-disease risksThe FDA approved the weight-loss drug Wegovy as a treatment to reduce cardiovascular risk in adults who are overweight, the first approval of its kind.
Les mer »
Wegovy, the weight-loss medication, gets FDA approval for use as heart disease prevention drugWegovy has been FDA-approved for heart disease prevention. The semaglutide, originally approved for weight loss, is now approved to reduce the risk of cardiovascular death, heart attack and stroke.
Les mer »